https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2016-01598
Olaparib, Durvalumab, and Tremelimumab in Treating Patients with Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer with BRCA1 or...
olaparibdurvalumabtremelimumabtreatingpatients